Ellison Mark Jason Heath - Net Worth and Insider Trading
Ellison Mark Jason Heath Net Worth
The estimated net worth of Ellison Mark Jason Heath is at least $387,208 dollars as of 2024-05-05. Ellison Mark Jason Heath is the Chief Development Officer of Opiant Pharmaceuticals Inc and owns about 18,751 shares of Opiant Pharmaceuticals Inc (OPNT) stock worth over $387,208. Details can be seen in Ellison Mark Jason Heath's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ellison Mark Jason Heath has not made any transactions after 2023-01-27 and currently still holds the listed stock(s).
Transaction Summary of Ellison Mark Jason Heath
Ellison Mark Jason Heath Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ellison Mark Jason Heath owns 1 companies in total, including Opiant Pharmaceuticals Inc (OPNT) .
Click here to see the complete history of Ellison Mark Jason Heath’s form 4 insider trades.
Insider Ownership Summary of Ellison Mark Jason Heath
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| OPNT | Opiant Pharmaceuticals Inc | 2023-01-27 | other: UK Managing Director |
Ellison Mark Jason Heath Latest Holdings Summary
Ellison Mark Jason Heath currently owns a total of 1 stock. Ellison Mark Jason Heath owns 18,751 shares of Opiant Pharmaceuticals Inc (OPNT) as of January 27, 2023, with a value of $387,208.
Latest Holdings of Ellison Mark Jason Heath
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| OPNT | Opiant Pharmaceuticals Inc | 2023-01-27 | 18,751 | 20.65 | 387,208 |
Holding Weightings of Ellison Mark Jason Heath
Ellison Mark Jason Heath Form 4 Trading Tracker
According to the SEC Form 4 filings, Ellison Mark Jason Heath has made a total of 3 transactions in Opiant Pharmaceuticals Inc (OPNT) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Opiant Pharmaceuticals Inc is the sale of 610 shares on January 27, 2023, which brought Ellison Mark Jason Heath around $12,359.
Insider Trading History of Ellison Mark Jason Heath
- 1
Ellison Mark Jason Heath Trading Performance
Ellison Mark Jason Heath Ownership Network
Ellison Mark Jason Heath Owned Company Details
What does Opiant Pharmaceuticals Inc do?
Who are the key executives at Opiant Pharmaceuticals Inc?
Ellison Mark Jason Heath is the other: UK Managing Director of Opiant Pharmaceuticals Inc. Other key executives at Opiant Pharmaceuticals Inc include other: General Counsel Brian Gorman , Chief Scientific Officer Phil Skolnick , and director & 10 percent owner & Chief Executive Officer Roger Crystal .
Opiant Pharmaceuticals Inc (OPNT) Insider Trades Summary
Over the past 18 months, Ellison Mark Jason Heath made 3 insider transaction in Opiant Pharmaceuticals Inc (OPNT) with a net sale of 2,885. Other recent insider transactions involving Opiant Pharmaceuticals Inc (OPNT) include a net sale of 7,570 shares made by Roger Crystal , a net sale of 2,556 shares made by David D O'toole , and a net sale of 2,270 shares made by Phil Skolnick .
In summary, during the past 3 months, insiders sold 0 shares of Opiant Pharmaceuticals Inc (OPNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,038 shares of Opiant Pharmaceuticals Inc (OPNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 17,038 shares.
Opiant Pharmaceuticals Inc (OPNT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Opiant Pharmaceuticals Inc Insider Transactions
Ellison Mark Jason Heath Mailing Address
Above is the net worth, insider trading, and ownership report for Ellison Mark Jason Heath. You might contact Ellison Mark Jason Heath via mailing address: C/o Opiant Pharmaceuticals, Inc., 201 Santa Monica Blvd., Suite 500, Santa Monica Ca 90401.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
